Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT2CJVK)

• DTT Name: Adrenergic receptor beta-2 (ADRB2) DTT Info
• Gene Name: ADRB2

Molecule-Related Drug & Molecule List

19 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arformoterol	DMYM974	Chronic obstructive pulmonary disease	CA22	Approved	[1]
Bambuterol	DMKLSHF	Asthma	CA23	Approved	[2]
Clenbuterol	DMCKYZ5	Chronic breathing disorder	7A4Z	Approved	[3]
Fenoterol	DMIP3ZV	Asthma	CA23	Approved	[4]
Formoterol	DMSOURV	Allergic asthma	CA23.0	Approved	[5]
GW642444	DMV4KOA	Asthma	CA23	Approved	[6]
Indacaterol	DMQJHR7	Chronic obstructive pulmonary disease	CA22	Approved	[7]
Isoetharine	DMITSEH	Asthma	CA23	Approved	[8]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[9]
Levalbuterol	DM5YBO1	Asthma	CA23	Approved	[10]
Metaproterenol Sulfate	DMTQS9A	Asthma	CA23	Approved	[11]
Olodaterol	DM62B78	Chronic obstructive pulmonary disease	CA22	Approved	[12]
Pirbuterol	DMI5678	Asthma	CA23	Approved	[13]
Procaterol	DM1M0Q4	Asthma	CA23	Approved	[14]
Ritodrine	DM4V6RL	Premature labour	JB00	Approved	[8]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[15]
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[16]
Terbutaline	DMD4381	Asthma	CA23	Approved	[17]
Vilanterol	DMF5EK1	Chronic obstructive pulmonary disease	CA22	Approved	[18]

17 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK642444	DMUVZAO	Chronic obstructive pulmonary disease	CA22	Phase 3	[19]
ICI 118,551	DM3OU54	Gastric adenocarcinoma	2B72	Phase 3	[20]
PT005	DMTSN8L	Chronic obstructive pulmonary disease	CA22	Phase 3	[21]
QVA-149	DMSFX75	Chronic obstructive pulmonary disease	CA22	Phase 3	[7]
BUCINDOLOL	DMV52CP	Atrial fibrillation	BC81.3	Phase 2/3	[22]
APD-209	DMNQ7DV	Cachexia	MG20	Phase 2	[23]
AZD-2115	DMGQSVX	Chronic obstructive pulmonary disease	CA22	Phase 2	[24]
AZD-3199	DME8Z5M	Asthma	CA23	Phase 2	[25]
Carmoterol	DMN6TKI	Chronic obstructive pulmonary disease	CA22	Phase 2	[7]
GSK961081	DM6DKF9	Chronic obstructive pulmonary disease	CA22	Phase 2	[26]
LAS 100977	DMPRZX4	Chronic obstructive pulmonary disease	CA22	Phase 2	[27]
MN-221	DMBX2RE	Aging skin	EE40	Phase 2	[28]
R-salbutamol sulphate	DMGLCVU	Skin infection	1F28-1G0Z	Phase 2	[29]
TA-2005	DMMWPSQ	Chronic obstructive pulmonary disease	CA22	Phase 2	[30]
THRX-198321	DM1BYNF	Chronic obstructive pulmonary disease	CA22	Phase 2	[31]
KUL-7211	DMKFVX5	Neurogenic bladder dysfunction	GC01.4	Phase 1	[32]
L-796568	DMXKO1L	Obesity	5B81	Phase 1	[33]

12 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meluadrine	DMEQDHP	Premature ejaculation	HA03.0Z	Discontinued in Preregistration	[34]
Broxaterol	DMRA6H5	Asthma	CA23	Discontinued in Phase 3	[35]
Sibenadet	DMYQT2V	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 3	[36]
GSK-159797	DMTZBXQ	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[30]
GSK159802	DM8J2AV	Asthma	CA23	Discontinued in Phase 2	[6]
Milveterol	DMF1IH5	Asthma	CA23	Discontinued in Phase 2	[6]
PF-610355	DM6XEQA	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[37]
Picumeterol	DMA13WI	Asthma	CA23	Discontinued in Phase 2	[38]
AR-C-89855	DM9HZ8D	Chronic obstructive pulmonary disease	CA22	Terminated	[39]
DPI-201-106	DM1AQVE	Cardiovascular disease	BA00-BE2Z	Terminated	[40]
L-755507	DMPWBNU	N. A.	N. A.	Terminated	[41]
RP-58802B	DMQZ2JA	Asthma	CA23	Terminated	[42]

11 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(R,R)-(-)-fenoterol	DM3FQYS	Discovery agent	N.A.	Investigative	[43]
(R,S)-(-)-fenoterol	DMETQBI	Discovery agent	N.A.	Investigative	[43]
(S,R)-(+)-fenoterol	DMA30RW	Discovery agent	N.A.	Investigative	[43]
1-(2-allylphenoxy)-3-morpholinopropan-2-ol	DMLV0PQ	Discovery agent	N.A.	Investigative	[44]
1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol	DMK209P	Discovery agent	N.A.	Investigative	[44]
2-fluoronorepinehprine	DMX34TL	Discovery agent	N.A.	Investigative	[45]
Butoxamine	DM7XN2J	Discovery agent	N.A.	Investigative	[46]
D 2343	DM1E5C4	Discovery agent	N.A.	Investigative	[47]
Dichloroisoproterenol	DMSZ7UE	Discovery agent	N.A.	Investigative	[48]
GNF-PF-1694	DM4JZ9A	Discovery agent	N.A.	Investigative	[40]
[3H]CGP12177	DMZN1A3	Discovery agent	N.A.	Investigative	[41]

References

• [1] Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
• [2] Enantiomeric separation of beta2-agonists on macrocyclic antibiotic chiral stationary phases in high performance liquid chromatography. Pharmazie. 2007 Nov;62(11):836-40.
• [3] Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
• [4] Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.
• [5] Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
• [6] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [7] Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [10] Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
• [11] Male--female differences in the impact of beta-adrenoceptor stimulation on resistance to experimental metastasis: exploring the effects of age and ... J Neuroimmunol. 2008 Jan;193(1-2):113-9.
• [12] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [13] Inhaled beta agonists. Respir Care. 2007 Jul;52(7):820-32.
• [14] Inhalation and incubation with procaterol increases diaphragm muscle contractility in mice. Allergol Int. 2007 Sep;56(3):285-91.
• [15] Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
• [16] Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
• [17] Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline. Pharmacology. 1975;13(3):201-11.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353).
• [19] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [20] Selective beta 2-adrenoceptor antagonists: derivatives of ICI 118,551 and a binary aryloxypropanolamine. J Pharm Pharmacol. 1988 Nov;40(11):803-5.
• [21] Clinical pipeline report, company report or official report of Pearl Therapeutics.
• [22] Bucindolol has serotonin and alpha-adrenoceptor blocking properties. J Cardiovasc Pharmacol. 1985;7 Suppl 7:S67-9.
• [23] Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Retraction in: Drug Des Devel Ther. 2013; 7: 1385.
• [24] Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115. Expert Opin Ther Pat. 2012 Nov;22(11):1377-83.
• [25] Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting beta2-adrenoreceptor agonist (uLABA). Drug Des Devel Ther. 2015; 9: 753-762.
• [26] Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and 2-adrenoceptor agonist properties.J Pharmacol Exp Ther.2014 Oct;351(1):190-9.
• [27] Pharmacological characterization of abediterol, a novel inhaled beta(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. J Pharmacol Exp Ther. 2012 Aug;342(2):497-509.
• [28] Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. J Obstet Gynaecol Res. 2009 Jun;35(3):405-13.
• [29] Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax. 1997 Oct;52(10):849-52.
• [30] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [31] THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol. 2011 Mar;79(3):389-99.
• [32] The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.Urol Res.2005 Dec;33(6):409-14.
• [33] Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic pr... Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9.
• [34] Effects of meluadrine tartrate and ritodrine hydrochloride on oxytocin-induced uterine contraction, uterine arterial blood flow and maternal cardiovascular function in pregnant goats. Jpn J Pharmacol. 2002 Oct;90(2):107-13.
• [35] Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment. Respiration. 1989;55 Suppl 2:15-9.
• [36] The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a... Respir Med. 2003 Jan;97 Suppl A:S23-33.
• [37] Inhalation by design: novel ultra-long-acting beta(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem. 2010 Sep 23;53(18):6640-52.
• [38] Picumeterol: dissociation of improvement in lung function and reduction of airways hyperresponsiveness in asthmatics. Br J Clin Pharmacol. 1997 Feb;43(2):169-76.
• [39] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013263)
• [40] Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5391-5.
• [41] (4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. J Med Chem. 2001 Apr 26;44(9):1456-66.
• [42] RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. Pulm Pharmacol. 1992 Sep;5(3):203-12.
• [43] Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem. 2007 Jun 14;50(12):2903-15.
• [44] A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404.
• [45] Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines. Bioorg Med Chem. 2009 Dec 1;17(23):7987-92.
• [46] Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92.
• [47] A new beta 2-adrenoceptor agonist--D 2343--with long duration. Inhalation comparison with terbutaline in asthmatics. Allergy. 1984 Aug;39(6):485-9.
• [48] The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists. J Med Chem. 1994 May 13;37(10):1518-25.